Nyrada Advances Xolatryp Phase IIa Trial with AU$6.74M Cash and Expanded Oncology Research

• Ethics approval received for Xolatryp Phase IIa trial in myocardial infarction
• Patient recruitment to start April 2026 at confirmed hospital sites
• AU$6.74 million cash on hand with AU$2.45 million R&D tax rebate expected
• Preclinical studies initiated for oncology and cardioprotection against chemotherapy
• Composition of matter patent published, pending grant

Phase IIa Trial Ready to Roll

Nyrada Inc (ASX:NYR) has cleared a crucial hurdle with Human Research Ethics Committee approval to launch its Phase IIa clinical trial of Xolatryp®, targeting heart attack patients undergoing angioplasty with stenting. Patient recruitment is set to kick off in April 2026 across confirmed hospital sites, marking a key step in assessing the drug's safety and preliminary efficacy.

This randomised, double-blind, placebo-controlled study will primarily focus on safety endpoints but also explore secondary measures such as cardiac function, injury extent, biomarker levels like troponin I, and arrhythmia incidence. As with many early-stage trials, efficacy data will only emerge after study completion. The company plans to provide periodic recruitment and safety updates, maintaining investor visibility.

Broadening Research Horizons with Oncology Focus

Beyond cardioprotection, Nyrada has initiated preclinical animal studies to evaluate Xolatryp’s potential in oncology, specifically its ability to protect against anthracycline-induced cardiotoxicity. Doxorubicin, a widely used chemotherapy agent, carries a known risk of cardiac damage, and scientific literature hints that Xolatryp may mitigate this effect. This diversification could open new therapeutic avenues if early results prove promising.

The company is also preparing an Investigational New Drug application for the US FDA, aiming to extend its myocardial ischemia reperfusion injury program internationally; a move that could broaden clinical and commercial prospects if approved.

Financial Position and Intellectual Property Progress

At quarter-end 31 March 2026, Nyrada reported a cash balance of AU$6.74 million, down slightly from AU$7.12 million at December 2025 but bolstered by AU$506,000 from option exercises during the period. Operating cash outflows were approximately AU$970,000, reflecting ongoing R&D and corporate costs. The company estimates receiving an R&D tax rebate of AU$2.45 million for FY2025, revised upward from a prior AU$2.16 million forecast, with receipt expected before the end of the 2026 financial year following resolution of overseas research approvals.

In intellectual property news, Nyrada’s composition of matter patent for Xolatryp was published late in the quarter, initiating the typical three to four-year process toward grant and securing 20 years of protection from the priority date. This milestone strengthens the company’s competitive moat around its lead candidate.

Payments to related parties, including director fees and CEO salary, totalled AU$219,000 for the quarter, consistent with prior periods.

This update follows earlier reports of Nyrada’s financials and trial progress, including the Xolatryp Advances as Losses Deepen to $3.19M in H1 2026 where the company detailed its Phase IIa preparations and cash position. The current report confirms steady advancement with patient recruitment imminent and expanded research efforts underway.

Bottom Line?

Nyrada’s Phase IIa trial launch and expanded oncology studies position it at a pivotal juncture, but clinical outcomes and FDA approvals remain critical milestones ahead.

Questions in the middle?

• Will early safety and efficacy data from the Phase IIa trial support further clinical development?
• How quickly will the FDA respond to Nyrada’s IND application, and what impact could this have on trial scope?
• Can Xolatryp’s potential cardioprotective effects in oncology translate into a viable new indication?